To describe incidence, health care use, and cost trends for infants with neonatal abstinence syndrome (NAS) who are covered by Medicaid compared with other infants. We used 2004We used -2014 hospital birth data from the National Inpatient Sample, a nationally representative sample of hospital discharges in the United States (N = 13 102 793). Characteristics and trends among births impacted by NAS were examined by using univariate statistics and logistic regression.
The incidence of neonatal abstinence syndrome (NAS) rose sharply between 2000 and 2012 as the opioid epidemic expanded across the United States. 1 -3 NAS is a withdrawal syndrome that occurs in infants who are exposed to opioids in utero. The syndrome is characterized by tremors, irritability, poor feeding, respiratory distress, and seizures, all of which develop shortly after birth. 4 Infants with NAS have longer hospital stays, higher rates of readmission, and are more likely than nonopioidexposed newborns to require care in the NICU for management of their symptoms. 5 -7 Maternal opioid use and NAS disproportionately impact lowincome women and infants who receive medical care covered by Medicaid. 3, 5 Although Medicaid pays for the majority of NAS-related births, the incidence of NAS among births financed by Medicaid remains poorly defined. 3, 5 Furthermore, although reports of hospital costs for NAS-related care exist, there are no data describing aggregate NASrelated hospital costs among infants enrolled in Medicaid, nationally. 8, 9 Hospital costs are important to consider because Medicaid does not reimburse on the basis of charges but on a schedule often closer to costs. Information regarding NAS incidence and costs could help state and federal health officials target efforts to improve care delivery for infants with the syndrome, expand treatment for pregnant women, and prevent NAS. For these reasons, Congress called on the Government Accountability Office to report "the proportion of children born in the United States with NAS who are eligible for medical assistance under State Medicaid programs…and the costs associated with coverage under such programs." 10 However, the subsequent Government Accountability Office report was largely based on qualitative data, because little quantitative data are available to guide such an overview. 11 We sought to characterize the impact of NAS among Medicaid beneficiaries by addressing the following 3 important and unanswered questions: (1) What is the incidence of NAS among Medicaid-financed births, nationally, and how has it changed over time?; (2) 
METHODS

Study Design and Setting
We conducted a serial crosssectional analysis by using data from the 2004 through 2014 National Inpatient Sample (NIS) compiled by the Healthcare Cost and Utilization Project of the Agency for Healthcare Research and Quality. 12 The NIS is the largest annual all-payer database of hospital discharges in the United States. It includes patient and hospital-level data from more than 1000 nonfederal hospitals in 46 states and encompasses 97% of the US population. Before 2012, the NIS sample included all discharges from 20% of US hospitals. Beginning in 2012, the NIS sampling frame changed to 20% of discharges from all US hospitals. To account for this sampling redesign, we applied trend weights provided by the Healthcare Cost and Utilization Project to allow for comparison across years.
Identification of Sample
Our sample consisted of infant discharge records of all hospital births from 2004 through 2014 in the NIS. Births were identified by using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes V30.0× to V39.0×. Infants with NAS were identified if ICD-9-CM code 779.5 was listed in any diagnosis field. We excluded cases of iatrogenic NAS that occur when an infant is exposed to opioids after birth, using previously described methods. 1, 3, 5 The NIS provides a primary payer for each hospital discharge. For purposes of this study, the primary payer was categorized as either private, Medicaid, or uninsured. Discharges with any public primary payer were categorized as Medicaid because Medicaid paid for >99% of birth-related discharges covered by a public payer in all our sampled years. 5 
Characteristics of Infants With NAS Compared With Other Infants
We examined characteristics of infants with NAS who were enrolled in Medicaid and compared them to (1) infants enrolled in Medicaid without NAS, and (2) infants enrolled in private insurance with NAS. We compared differences in sex, income quartile of patient's zip code, and rural status. We also estimated incidence of preterm deliveries (ICD-9-CM codes 765.21-765.28) and presence of comorbidities known to be common among infants with NAS by using previously described methods (ie, respiratory diagnoses, low birth weight, seizures, or feeding difficulty). 5 
Outcome Measures
NAS Incidence
We first calculated the annual national incidence of NAS among all infants per 1000 hospital births. We then determined the annual incidence of NAS within Medicaid and private payer subgroups. The purpose of this subgroup analysis was to ultimately determine costs among infants whose care was financed by a health insurance entity, and thus, we did not examine NAS incidence among uninsured infants.
Health Care Use and Costs
We compared the rate of hospital transfer to another facility, mean length of stay, and mean cost of birth hospitalization among infants with NAS who were enrolled in Medicaid to infants without NAS who were enrolled in Medicaid and to infants with NAS who were enrolled in private insurance.
To obtain hospital costs, we used Agency for Healthcare Research and Quality's cost-to-charge ratio files to convert charges. 8, 12 We applied the cost-to-charge ratio to each charge in our analytic sample and inflationadjusted resultant costs to 2014 dollars by using the Consumer Price Index for All Urban Consumers. 13 We aggregated hospital costs for all NAS births covered by Medicaid in each year of our study. Less than 4% of NAS discharges were missing cost information. Next, we aggregated hospital costs for all births covered by Medicaid in each year of our study. We then determined the proportion of birth-related hospital costs due to NAS in each year of our study among infants covered by Medicaid. Similar analyses were conducted for total birth-related costs due to NAS among all-payers.
Finally, we estimated excess costs among infants covered by Medicaid due to NAS over the course of our study period by multiplying the number of weighted NAS births in each time period by the average cost for a non-NAS birth who were covered by Medicaid and subtracting these values from aggregated hospital costs for infants with NAS who were covered by Medicaid.
Data Analysis
We used weighted frequencies to describe characteristics of infants with NAS who were enrolled in Medicaid, infants without NAS who were enrolled in Medicaid, and infants with NAS who were enrolled in private insurance. Differences were compared by using Pearson's χ 2 tests. We similarly estimated health care use and mean hospital costs among these groups by using univariate frequencies and compared differences with χ 2 tests and t tests. To characterize broad time trends, we determined length of stay and mean hospital costs during 3 time periods (2004-2006 vs 2007-2010 vs 2011-2014) . Because transfer to another facility was only available for years 2010-2014, we did not examine changes in transfer rates over time.
We used multivariable negative binomial and logistic regression to compare length of stay and transfer rates, respectively, between infants with NAS enrolled in either Medicaid or private insurance. Our models accounted for year, sex, income quartile of patient's zip code, urban versus rural residence, hospital type (rural versus urban nonteaching versus urban teaching), and prematurity.
To obtain annual hospital costs for infants with and without NAS covered by Medicaid we used Stata's total commands with survey weights. We determined excess costs among infants with NAS covered by Medicaid using methods described in the previous section.
We used logistic regression and predictive margins to obtain unadjusted NAS incidence nationally and among infants who were enrolled in Medicaid or private insurance. NAS incidence is reported as NAS cases per 1000 hospital births.
All analyses were conducted by using Stata 15.0 (StataCorp, College Station, TX). Estimates are weighted, unless otherwise noted, to allow for nationally representative inferences and to account for changes to the NIS sampling strategy in 2012. We considered 2-sided P < .05 to be statistically significant. Our study was exempt from human subjects review per the Minneapolis Medical Research Foundation's policy on de-identified data sets.
RESULTS
Sample Characteristics
Our sample consisted of 9 Infants with NAS who were enrolled in Medicaid were significantly more likely to be male, reside in a rural county, and have comorbidities reflective of the syndrome than infants without NAS who were enrolled in Medicaid. Similarly, infants with NAS who were enrolled in Medicaid were more likely to live in poor and rural counties but were less likely to be diagnosed with a NAS-related comorbidity compared with infants with NAS enrolled in private insurance (Table 1) .
NAS Incidence
Between 2004 and 2014, the incidence of NAS in the United States increased from 1.5 per 1000 hospital births (95% CI, 1.2-1.9) to 8.0 per 1000 hospital births (95% CI, 7.2-8.7), a more than fivefold increase (Fig 1) . The rising incidence of NAS was driven in large part by a substantial increase in NAS among Medicaid covered births. In 2004, the incidence of NAS among Medicaidfinanced births was 2. 
Health Care Use and Costs
In unadjusted analyses, infants with NAS who were covered by Medicaid were significantly more likely to be transferred to another hospital for care than were infants without NAS who were covered by Medicaid or infants with NAS who were covered by private insurance between 2010 and 2014 ( Table 2) . In each time period we examined, infants with NAS who were covered by Medicaid had hospital stays that were significantly longer than infants without NAS who were covered by Medicaid or infants with NAS who were covered by private insurance ( Table 2) . Differences in transfer rates and length of stay between infants with NAS who were covered by Medicaid and private insurance persisted after controlling for patient and hospitallevel factors. In adjusted analyses, infants with NAS who were covered by Medicaid were more likely to be transferred to another hospital for care (8.6% vs 7.1%; P = .02) and to have longer lengths of stay (16.5 days vs 14.6 days; P < .001) compared with infants with NAS who were covered by private insurance.
The mean cost for an infant with NAS was significantly higher than for an infant without NAS. (Fig 2) . As hospital costs for infants with NAS who were covered by Medicaid increased from 2004 through 2014, the proportion of birth-related costs due to NAS also increased (Fig 3) . 
FIGURE 2
Total hospital costs for NAS among infants who were enrolled in Medicaid.
FIGURE 3
Proportion of birth-related hospital costs due to NAS among infants who were enrolled in Medicaid. Ultimately, a public health approach that targets patient-, family-, and community-level factors will be necessary to prevent women from developing opioid use disorders. 30 Individual level predictors of opioid use disorders include mental health disorders and preexisting substance use disorders. 31 Screening, referral, and treatment for these conditions may reduce the incidence of opioid use disorders among reproductiveage women. At the family level, adolescents with strained parental relationships are at increased risk of opioid use disorders and may benefit from family-based therapy. 32 At the community-level, low socioeconomic status and unemployment are strong predictors of opioid use. 33 Collaboration among a diverse set of stakeholders will be required at each level to reduce factors that contribute to opioid use among reproductiveaged women.
This study has several important limitations. NIS data are aggregated from hospital discharge information and reflect coding practices in which misclassification bias is possible. Current evidence suggests NAS is underreported in hospital billing data. 34 Therefore, the incidence and costs associated with NAS we report here are likely conservative. Alternatively, rising NAS incidence may be because of an improved awareness and recognition of the clinical syndrome over time or iatrogenic cases of NAS not accounted for in our exclusion criteria. However, the associated increase in maternal opioid use described elsewhere 3, 5 and opioid use trends among the general population 35 do not suggest a progressive diagnostic bias in NAS. Finally, because of data limitations, we were not able to calculate statelevel cost variation.
CONCLUSIONS
Federal and state Medicaid program administrators have the opportunity to implement policies that promote prevention and treatment of NAS.
Reducing NAS incidence will require the adoption of a public health approach to opioid use disorders among reproductive-aged women.
